Millennium Pharmaceuticals Limited

Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Takeda Pharmaceutical Company Limited

Francois Soucy

Indu T Bharathan

Paul E Fleming

Yingchun Ye

Jeffrey P Ciavarri

Tricia J Vos

Gang Li

Tzu-Tshin Wong

Mario Girard

Prakash Raman

Shomir Ghosh

Dominic J Reynolds

Kenneth M Gigstad

Amy M Elder

Qing Ye

Alfredo C Castro

Stephen G Stroud

Steven P Langston

He Xu

Yongbo Hu

Courtney A Cullis

Michael D Sintchak

Chris Blackburn

Jeffrey L Gaulin

Krista E Gipson

Roushan Afroze

Jouhara Chouitar

Natalie D'Amore

Janice Lee

Mansoureh Rezaei

Louis Grenier

Julian Adams

Kenneth Gordon Carson

Olaf Ritzeler

Vito J Palombella

Matthew O Duffey

Tianlin Xu

Hormoz Mazdiyasni

Jianping Guo

Wayne William Hancock

Julie Fields Liu

Kevin Sprott

Michael E Hepperle

Sian Griffiths

Louis Plamondon

Zhan Shi

Stepan Vyskocil

Geraldine C B Harriman

Hong Myung Lee

Stephen J Brand

Brian Scott Freeze

Wayne W Hancock

Jeremy D Little

Peter J Elliott

David A Janowick

Marlo Girard

Robert S Murray

Raman Prakash

Hormoz Mazdiyashi

Alfred L Goldberg

Vito Palombella

Natalie D'amore

The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R, R, R, R, R, L, L, m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Heteroaryls and uses thereof

This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R, R, o, R, W and Rand subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease. 

Quinazoline and quinoline compounds and uses thereof

The present invention provides a compound of formula I: 

Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein Y is and W, Z, X, R, Rand Rare defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.

Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.

Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists

This invention provides compounds of formula I: 

Thiolactams and uses thereof

The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions. 

Compounds useful as antagonists of CCR2

The present invention provides compounds of general formula (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and Rare defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions. 

Growing community of inventors

Stoneham, MA, United States of America

Francois Soucy